Lipid formulations of amphotericin B significantly improve outcome in solid organ transplant recipients with central nervous system cryptococcosis.
Lipid formulations of amphotericin B significantly improve outcome in solid organ transplant recipients with central nervous system cryptococcosis.
复制标题
两性霉素 B 的脂质制剂可显着改善患有中枢神经系统隐球菌病的实体器官移植受者的预后。
DOI：
10.1086/647948
复制
发表时间：
2009
期刊：
影响因子：
--
通讯作者：
Pur
中科院分区：
文献类型：
--
作者：
Sun,Hsin-Yun;Alexander,BarbaraD;Lortholary,Olivier;Dromer,Francoise;Forrest,GraemeN;Lyon,GMarshall;Somani,Jyoti;Gupta,KrishanL;delBusto,Ramon;Pruett,TimothyL;Sifri,CostiD;Limaye,AjitP;John,GeorgeT;Klintmalm,GoranB;Pur
Background.Whether outcome of central nervous system (CNS) cryptococcosis in solid organ transplant recipients treated with lipid formulations of amphotericin B is different from the outcome of the condition treated with amphotericin B deoxycholate (AmBd) is not known.Methods.We performed a multicenter study involving a cohort comprising consecutive solid organ transplant recipients with CNS cryptococcosis.Results.Of 75 patients treated with polyenes as induction regimens, 55 (73.3%) received lipid formulations of amphotericin B and 20 (26.7%) received AmBd. Similar proportions of patients in both groups had renal failure at baseline (P=.94). Overall, mortality at 90 days was 10.9% in the group that received lipid formulations of amphotericin B and 40.0% in the group that received AmBd. In univariate analysis, nonreceipt of calcineurin inhibitors (P=.034), renal failure at baseline (P=.016), and fungemia (P=.003) were significantly associated with mortality. Compared with AmBd, lipid formulations of amphotericin B were associated with a lower mortality (P=.007). Mortality did not differ between patients receiving lipid formulations of amphotericin B with or without flucytosine (P=.349). In stepwise logistic regression analysis, renal failure at baseline (odds ratio [OR], 4.61; 95% confidence interval [CI], 1.02–20.80; P=.047) and fungemia (OR, 10.66; 95% CI, 2.08–54.55; P=.004) were associated with an increased mortality, whereas lipid formulations of amphotericin B were associated with a lower mortality (OR, 0.11; 95% CI, 0.02–0.57; P=.008).Conclusions.Lipid formulations of amphotericin B were independently associated with better outcome and may be considered as the first-line treatment for CNS cryptococcosis in these patients.
